Response to the Comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH) on the 5th edition of the World Health Organization classification of haematolymphoid tumors.
作者信息
Siebert Reiner, Schuh Anna, Ott German, Cree Ian A, Du Ming-Qing, Ferry Judith, Hochhaus Andreas, Naresh Kikkeri N, Solary Eric, Khoury Joseph D
机构信息
Institute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.
Department of Oncology, University of Oxford, Oxford, UK.
出版信息
Leukemia. 2023 May;37(5):1170-1172. doi: 10.1038/s41375-023-01872-6. Epub 2023 Mar 27.
Abstract
摘要
相似文献
1
Response to the Comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH) on the 5th edition of the World Health Organization classification of haematolymphoid tumors.
Leukemia. 2023 May;37(5):1170-1172. doi: 10.1038/s41375-023-01872-6. Epub 2023 Mar 27.
2
The 5th edition of the WHO classification of haematolymphoid tumors: comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Leukemia. 2023 Apr;37(4):946-947. doi: 10.1038/s41375-023-01821-3. Epub 2023 Jan 27.
3
Cytogenetics in the management of acute myeloid leukemia and histiocytic/dendritic cell neoplasms: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Curr Res Transl Med. 2023 Oct-Dec;71(4):103421. doi: 10.1016/j.retram.2023.103421. Epub 2023 Oct 16.
4
Cytogenetics in the management of "chronic myeloid leukemia": an update by the Groupe francophone de cytogénétique hématologique (GFCH).
Ann Biol Clin (Paris). 2016 Oct 1;74(5):511-515. doi: 10.1684/abc.2016.1151.
5
Cytogenetics in the management of hematologic malignancies: an update by the Groupe francophone de cytogénétique hématologique (GFCH).
Ann Biol Clin (Paris). 2016 Oct 1;74(5):509-510. doi: 10.1684/abc.2016.1150.
6
Cytogenetics in the management of myeloproliferative neoplasms, mastocytosis and myelodysplastic/myeloproliferative neoplasms: Guidelines from the Group Francophone de Cytogénétique Hématologique (GFCH).
Curr Res Transl Med. 2023 Oct-Dec;71(4):103424. doi: 10.1016/j.retram.2023.103424. Epub 2023 Oct 20.
7
Cytogenetics in the management of acute myeloid leukemia: an update by the Groupe francophone de cytogénétique hématologique (GFCH).
Ann Biol Clin (Paris). 2016 Oct 1;74(5):535-546. doi: 10.1684/abc.2016.1155.
8
Cytogenetics in the management of multiple myeloma: an update by the Groupe francophone de cytogénétique hématologique (GFCH).
Ann Biol Clin (Paris). 2016 Oct 1;74(5):588-595. doi: 10.1684/abc.2016.1178.
9
Cytogenetics in the management of chronic lymphocytic leukemia: an update by the Groupe francophone de cytogénétique hématologique (GFCH).
Ann Biol Clin (Paris). 2016 Oct 1;74(5):561-567. doi: 10.1684/abc.2016.1177.
10
Cytogenetics in the management of B-cell acute lymphoblastic leukemia: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Curr Res Transl Med. 2023 Oct-Dec;71(4):103434. doi: 10.1016/j.retram.2023.103434. Epub 2023 Nov 24.
引用本文的文献
1
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes.
Blood Adv. 2024 Dec 24;8(24):6297-6307. doi: 10.1182/bloodadvances.2024013327.
2
What is new in the 5th edition of the World Health Organization classification of mature B and T/NK cell tumors and stromal neoplasms?
J Hematop. 2024 Jun;17(2):71-89. doi: 10.1007/s12308-024-00585-8. Epub 2024 Apr 29.
3
Immunogenetics in hematopathology and hematology: why a common language is important.
Leukemia. 2024 Jul;38(7):1474-1476. doi: 10.1038/s41375-024-02260-4. Epub 2024 Apr 25.
4
Precision hematology: Navigating the evolution of diagnostic classifications in the era of globalized medicine.
Hemasphere. 2024 Apr 4;8(4):e65. doi: 10.1002/hem3.65. eCollection 2024 Apr.
5
Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).
Curr Oncol. 2023 Jun 27;30(7):6177-6196. doi: 10.3390/curroncol30070459.
本文引用的文献
1
The 5th edition of the WHO classification of haematolymphoid tumors: comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Leukemia. 2023 Apr;37(4):946-947. doi: 10.1038/s41375-023-01821-3. Epub 2023 Jan 27.
2
The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high-risk clonal cytopenia of unknown significance.
Genes Chromosomes Cancer. 2023 Mar;62(3):139-151. doi: 10.1002/gcc.23107. Epub 2022 Nov 30.
3
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
4
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.
5
HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions.
Leukemia. 2021 Nov;35(11):3040-3043. doi: 10.1038/s41375-021-01436-6. Epub 2021 Oct 6.
6
Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53.
Blood. 2019 Nov 21;134(21):1821-1831. doi: 10.1182/blood.2019001187.
7
Clinical significance of isolated del(7p) in myeloid neoplasms.
Leuk Res. 2017 Apr;55:18-22. doi: 10.1016/j.leukres.2017.01.016. Epub 2017 Jan 16.
8
High-resolution genomic profiling in hairy cell leukemia-variant compared with typical hairy cell leukemia.
Leukemia. 2011 Jul;25(7):1189-92. doi: 10.1038/leu.2011.47. Epub 2011 Mar 25.
Zotero 插件